Milnacipran for the management of fibromyalgia syndrome

Journal of Pain Research

Volumn 3, Issue , 2010, Pages 15-24

  Ormseth, Michelle J ^a   Eyler, Anne E ^a   Hammonds, Cara L ^a   Boomershine, Chad S ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Fibromyalgia; Milnacipran; Treatment

Indexed keywords

AMITRIPTYLINE; DESVENLAFAXINE; DULOXETINE; MILNACIPRAN; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VENLAFAXINE;

BLOOD PRESSURE; CLINICAL TRIAL; COGNITION; CONSTIPATION; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FATIGUE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; MORNING DOSAGE; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PAIN ASSESSMENT; REVIEW; SIDE EFFECT; SLEEP; TACHYCARDIA; TREATMENT DURATION; VOMITING; XEROSTOMIA;

EID: 77953403456     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol. 2007;34:1415-1425.
2. Gran JT. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol. 2003;17:547-561.
3. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse ourcomesm comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromylagia. J Rheum. 2004;31:695-700.
4. Middleton GD, McFarlan JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosis. Arthritis Rheum. 1994;37:1181-1188.
5. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
6. Wolfe F. Stop using the American College of Rheumatology Criteria in the Clinic. J Rheumatol. 2003;30(8); 1671-162.
7. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536-541.
8. Wolfe F, Clauw D, Fitzcharles MA, et al. Clinical Diagnostic and Severity Criteria for Fibromyalgia. Arthitis Rheum 2009;60(10 supplement): S210. Presented at the 2009 ACR/ARHP Scientific Meeting Sunday October 18, 2009.
9. Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol. 2009;5:191-199.
10. Bennett RM, Friend R, Jones KD, et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120. Available at http://arthritisresearch.com/content/11/4/R120.
11. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: The pathophysiology of fibromyalgia. Ann Intern Med. 2007;146:726-734.
12. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance inaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333-1343.
13. Giesecke T, Gracely RH, Williams DA, et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain chort. Arthritis Rheum. 2005;52:1577-1584.
14. Cook DB, Lange G, Ciccone DS, et al. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004;31:364-378.
15. Dubner R, Hargreaves KM. The neurobiology of pain and its modulation. Clin J Pain. 1989;5 Suppl 2:S1-S4.
16. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic anime metabolites in fibromyalgia/ fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550-556.
17. Van Koulil S, Effing M, Kraaimaat FW, van Lankveld W, van Helmond T, Cats H, et al. Cognitive-behavioral therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Ann Rheum Dis. 2007;66:571-581.
18. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-95.
19. Obata H, Saito S, Koizuka S, et al. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg. 2005;100:1306-1410.
20. Vaishnavi SN, Nemeroff CB, Plott SJ, et al. Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004;55:320-322.
21. Leo R, Brooks VL. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006;7:637-642.
22. Scholtz BA, Hammonds CL, Boomershine CS. Duloxetine for the management of f ibromyalgia syndrome. J Pain Res. 2009; 2:99-108.
23. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004; 55:320-322.
24. Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511-521.
25. Puozzo C, Lens S, Reh C, et al. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet. 2005;44:977-988.
26. Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrineand serotonin-reuptake inhibitor. Am J Health Syst Pharm. 2005;62:2481-2490.
27. Puozzo C, Albin H, Vincon G, Deprez D, Raymond JM, Amouretti M. Pharmacokinetics of milnacipan in liver impairment. Eur J Drug Metab Pharmacokinet. 1998;23:273-279.
28. http://pi.lilly.com/us/cymbalta-pi.pdf. Accessed November 4, 2009.
29. Puozzo C, Pozet N, Deprez D, Baille P, Ung HL, Zech P. Pharmacokinetics of milnacipran in renal impairment. Eur J Drug Metab Pharmacokinet. 1998;23:280-6.
30. http://www.frx.com/pi/Savella_pi.pdf. accessed November 4, 2009.
31. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin. 2007; 23:175-184.
32. Clauw DJ. Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry. 2008;69(suppl 2):25-29.
33. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398-409.
34. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19 Suppl 1:S27-S35.
35. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005; 32:1975-1985.
36. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30:1988-2004.
37. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. BMJ. 2002;324:1193-1194.
38. Gracely RH, Kwilosz DM. The descriptor differential scale: applying psychophysical principles to clinical pain assessment. Pain. 1988;35:279-288.
39. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991; 18:728-733.
40. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
41. Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
42. Jenkins CD, Stanton BA, Niemcryk SJ, et al. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol. 1988; 41:313-321.
43. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25-40.
44. Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology. 2005;65(Suppl 4):S7-S19.
45. Goldenberg D, Clauw DJ, Palmer RH, et al. One-year durability of response to milnacipran treatment for fibromyalgia. Arthritis Rheum. 2007;56(Suppl 9):S603.
46. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15.
47. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed dose trial. Pain. 2008;136:432-444.
48. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, doubleblinded placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792-805.
49. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blinded, placebo-controlled, phase III trial of pregabalin in treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502-514.
50. Lecrubier Y, Pletan, Y, Solles A, Tournoux A, Magne V. Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharm. 1996;11(Suppl 4):29-33.
51. Kasper S, Pleatan Y, Solles A, Tournoux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharm. 1996;11(Suppl 4):35-39.
52. Nakagawa A, Watanabe N, Omori IM, et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009;(3):CD006529.